Running a biotech company means taking risks — deciding where to invest, for example, or what scientific targets to chase.
However, the sector faces another kind of risk, with a new administration in charge in Washington.
That’s the message Biogen chief executive Chris Viehbacher conveyed to Massachusetts Gov. Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts event in Waltham. Earlier in the week, the National Institutes of Health and other federal health agencies cancelled a flurry of meetings, as the incoming Trump administration gets settled.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.